Powder: -20°C for 3 years
In solvent: -80°C for 2 years
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.
Description | PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively. |
Targets&IC50 | FGFR1:39.9 nM (IC50), FGFR1 autophosphorylation:622 nM, FGFR1:42 nM (Ki) |
Synonyms | PD 161570 |
Molecular Weight | 532.51 |
Formula | C26H35Cl2N7O |
CAS No. | 192705-80-9 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 30 mg/ml (56.34 mM), Need ultrasonic
Ethanol: <53.25mg/ml
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD-161570 192705-80-9 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors Src EGFR FGFR PDGFR Inhibitor Fibroblast growth factor receptor HER1 kinases PD 161570 autophosphorylation PD161570 inhibit TGF-β Receptor ATP-competitive Epidermal growth factor receptor tyrosine Platelet-derived growth factor receptor disease anti-cancer angiogenesis ErbB-1 FGFR1 Transforming growth factor beta receptors cardiovascular anti-proliferation inhibitor